Viewing Study NCT02393157


Ignite Creation Date: 2025-12-24 @ 7:00 PM
Ignite Modification Date: 2026-04-09 @ 10:54 AM
Study NCT ID: NCT02393157
Status: RECRUITING
Last Update Posted: 2025-08-08
First Post: 2015-03-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Sponsor: New York Medical College
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module